Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

Accrued Expenses

3 Months Ended

Mar. 31, 2016

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

4. Accrued Expenses

Accrued expenses consist of the following:

		March 31, 2016 (unaudited)			December 31, 2015
Payroll and benefits		$	100,616		$	652,609
Clinical trials			255,000			365,277
Consulting			35,700			18,500
Professional fees			179,349			59,352
Insurance			340,000			-
Total accrued expenses		$	910,665		$	1,095,738